Unknown

Dataset Information

0

Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.


ABSTRACT: BACKGROUND:Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment. OBJECTIVE:To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD. METHODS:Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks. Respiratory parameters and plasma levels of multiple eicosanoids were recorded at baseline and after 4 weeks of aspirin therapy using the Asthma Control Test and Rhinoconjunctivitis Quality of Life Questionnaire. Respiratory function was evaluated using the FEV1 and nasal inspiratory peak flow. RESULTS:After aspirin treatment, respiratory symptoms improved in 16 patients, worsened in 12 patients, and did not change in 4 patients. Seven patients were unable to complete the desensitization protocol. Patients with symptom improvement had higher baseline plasma 15-hydroxyeicosatetraenoic acid (15-HETE) levels than did patients with symptom worsening: 7006 pg/mL (interquartile range, 6056-8688 pg/mL) versus 4800 pg/mL (interquartile range, 4238-5575 pg/mL), P = .0005. Baseline 15-HETE plasma levels positively correlated with the change in Asthma Control Test score (r = 0.61; P = .001) and in FEV1 after 4 weeks of aspirin treatment (r = 0.49; P = .01). It inversely correlated with Rhinoconjunctivitis Quality of Life Questionnaire score (r = -0.58; P = .002). Black and Latino patients were more likely to have symptom worsening on aspirin or fail to complete the initial desensitization than white, non-Latino patients (P = .02). CONCLUSIONS:In patients with AERD, low baseline 15-HETE plasma levels and black or Latino ethnicity are associated with worsening of respiratory symptoms during aspirin treatment.

SUBMITTER: Jerschow E 

PROVIDER: S-EPMC5491381 | biostudies-literature | 2017 Jul - Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.

Jerschow Elina E   Edin Matthew L ML   Pelletier Teresa T   Abuzeid Waleed M WM   Akbar Nadeem A NA   Gibber Marc M   Fried Marvin M   Lih Fred B FB   Gruzdev Artiom A   Bradbury J Alyce JA   Han Weiguo W   Hudes Golda G   Keskin Taha T   Schuster Victor L VL   Spivack Simon S   Zeldin Darryl C DC   Rosenstreich David D  

The journal of allergy and clinical immunology. In practice 20170131 4


<h4>Background</h4>Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment.<h4>Objective</h4>To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD.<h4>Methods</h4>Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks.  ...[more]

Similar Datasets

| S-EPMC6519056 | biostudies-literature
| S-EPMC7606335 | biostudies-literature
| S-EPMC5945343 | biostudies-literature
| S-EPMC7012664 | biostudies-literature
| S-EPMC3151506 | biostudies-literature
| S-EPMC4790533 | biostudies-other
2014-09-05 | GSE61129 | GEO
| S-EPMC4559084 | biostudies-literature
2014-09-05 | E-GEOD-61129 | biostudies-arrayexpress
| S-EPMC9292205 | biostudies-literature